Compare Harley-Davidson Inc (HOG) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harley-Davidson Inc vs Viatris Inc — how do they compare? Harley-Davidson Inc trades at $26.73 (market cap $2.78B), while Viatris Inc trades at $17.26 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 7.2× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays the higher dividend (2.8%). Which is the better fit depends on your goals — on Pluang, investors hold Harley-Davidson Inc for 91 Days and Viatris Inc for 57 Days on average.
| HOG | VTRS | |
|---|---|---|
Market Cap | $2.78B | $20.03B |
Volume | 2,966,389 | 14,109,977 |
Sector | Consumer Cyclical | Health |
52-Week High | $28.46 | $18.27 |
52-Week Low | $17.19 | $9.74 |
Typical Hold Time | 91 Days | 57 Days |
Enterprise Value | $3.20B | $32.15B |
Dividend Yield | 2.8% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $26.95, up 0.04% on the day, with a bullish technical signal and mixed earnings history. The company reported Q2 2026 EPS of $0.75, beating expectations, but revenue has declined from $5.8B in 2022 to $4.5B in 2025. Valuation ratios appear attractive with a P/E of 14.86 and P/B of 0.9, while analyst consensus is a hold with a $28.50 price target. Recent news includes a data breach investigation and a new product collaboration.
The outlook for HOG is cautious due to declining revenue and profit margins, offset by reasonable valuations and positive technical momentum. Key risks include tariff exposure, competitive pressures, and ongoing data security issues. Upside potential exists if the 'Back to the Bricks' strategy reverses sales trends, but investors should weigh fundamental weaknesses against technical strength.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
